Efficacy and safety of BVAC-C in HPV type 16- or 18–positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study

Efficacy and safety of BVAC-C in HPV type 16- or 18–positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study

BackgroundBVAC-C, a B cell– and monocyte-based immunotherapeutic vaccine transfected with recombinant HPV E6/E7, was well tolerated in HPV–positive recurrent cervical carcinoma patients in a phase I study. This phase IIa study investigates the antitumor activity of BVAC-C in patients with HPV 16– or...

Full description

Bibliographic Details
Main Authors: Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae, Eun-Suk Kang, Duck Cho, Yong-Man Kim, Kidong Kim, Jae-Weon Kim, Hee Seung Kim, Young-Tae Kim, Jung-Yun Lee, Myong Cheol Lim, Taegwon Oh, Boyeong Song, Insu Jeon, Myunghwan Park, Wu Hyun Kim, Chang-Yuil Kang, Byoung-Gie Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Immunology
Subjects:
HPV 16
HPV 18
cervical cancer
BVAC-C
therapeutic vaccine
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1371353/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1371353/full

Similar Items